Humacyte, Inc. (NASDAQ:HUMA) Receives $11.71 Consensus Price Target from Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned a consensus recommendation of “Buy” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $11.71.

A number of brokerages recently issued reports on HUMA. HC Wainwright started coverage on shares of Humacyte in a research report on Wednesday, May 14th. They set a “buy” rating and a $4.00 target price on the stock. Benchmark lowered their price objective on Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research report on Monday, June 9th. Finally, Wall Street Zen lowered shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Saturday.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $2.37 on Thursday. Humacyte has a 12-month low of $1.15 and a 12-month high of $9.79. The company has a market capitalization of $367.63 million, a PE ratio of -1.77 and a beta of 2.00. The firm’s 50-day moving average is $1.91 and its two-hundred day moving average is $3.15.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.46 million. On average, analysts forecast that Humacyte will post -1.27 EPS for the current fiscal year.

Insiders Place Their Bets

In other Humacyte news, CFO Dale A. Sander purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, April 10th. The stock was acquired at an average cost of $1.53 per share, with a total value of $30,600.00. Following the acquisition, the chief financial officer now owns 40,600 shares of the company’s stock, valued at approximately $62,118. This represents a 97.09% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Kathleen Sebelius purchased 50,000 shares of the firm’s stock in a transaction dated Tuesday, April 8th. The stock was acquired at an average cost of $1.32 per share, with a total value of $66,000.00. Following the completion of the acquisition, the director now directly owns 91,207 shares in the company, valued at approximately $120,393.24. This trade represents a 121.34% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 83,993 shares of company stock valued at $118,224 in the last ninety days. Corporate insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Humacyte by 10.8% in the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock valued at $28,294,000 after buying an additional 543,995 shares during the period. Northern Trust Corp boosted its stake in Humacyte by 11.5% during the 4th quarter. Northern Trust Corp now owns 901,194 shares of the company’s stock valued at $4,551,000 after purchasing an additional 92,708 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Humacyte in the 4th quarter worth approximately $99,000. Swiss National Bank lifted its stake in shares of Humacyte by 5.8% in the 4th quarter. Swiss National Bank now owns 172,100 shares of the company’s stock worth $869,000 after acquiring an additional 9,400 shares during the period. Finally, CenterBook Partners LP acquired a new stake in shares of Humacyte in the 4th quarter worth approximately $6,463,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.